Market Place
Sourcing Support
Femasys Appoints John Canning COO to Drive Execution & Growth
01 Apr 2026 //
GLOBENEWSWIRE
Femasys Reveals 2025 Financial Results And Corporate Update
31 Mar 2026 //
GLOBENEWSWIRE
Femasys Appoints Dr. Kenneth D. Eichenbaum To Board Of Directors
18 Mar 2026 //
GLOBENEWSWIRE
Femasys Reveals Inducement Grants Per Nasdaq LR 5635(C)(4)
27 Feb 2026 //
GLOBENEWSWIRE
Femasys Advances Global Access With Fembloc MDSAP Certification
26 Feb 2026 //
GLOBENEWSWIRE
Femasys Inks Swiss Deal for FemBloc, FemaSeed, Portfolio Products
03 Feb 2026 //
GLOBENEWSWIRE
Femasys Receives 180-Day Nasdaq Extension For Bid Price
14 Jan 2026 //
GLOBENEWSWIRE
Femasys Partners With Refuah Health to Expand FemaSeed Access
13 Jan 2026 //
GLOBENEWSWIRE
Pharmacyte Bio Monetizes Femasys Stake, Boosts Cash And Strategy
25 Nov 2025 //
BUSINESSWIRE
Femasys Announces Third Quarter Financial Results For 2025
14 Nov 2025 //
GLOBENEWSWIRE
Femasys Boosts Global Expansion With Second Fembloc Order
10 Nov 2025 //
GLOBENEWSWIRE
Femasys Gets FDA Nod to Begin Final FemBloc Ph, Secures $12M
03 Nov 2025 //
GLOBENEWSWIRE
Femasys Starts Post-Market Study For Fembloc® Birth Control
22 Oct 2025 //
GLOBENEWSWIRE
Femasys To Exhibit At The ASRM 2025 Scientific Congress & Expo
16 Oct 2025 //
GLOBENEWSWIRE
Femasys Expedites Fembloc® European Expansion Via Kebomed
25 Sep 2025 //
GLOBENEWSWIRE
Femasys Secures $8M for Fertility and Birth Control Launch
02 Sep 2025 //
GLOBENEWSWIRE
Femasys Reveals Q2 Financial Results for 2025
08 Aug 2025 //
GLOBENEWSWIRE
Femasys Secures First EU Order for FemBloc in Global Expansion
06 Aug 2025 //
GLOBENEWSWIRE
Femasys gets Australian, New Zealand approvals for FemaSeed®
01 Jul 2025 //
GLOBENEWSWIRE
Femasys Prices Public Offering and Private Placement at $4.5M
30 May 2025 //
GLOBENEWSWIRE
Femasys Plans Public Stock Offering with Private Placement
29 May 2025 //
GLOBENEWSWIRE
Femasys Reports Q1 2025 Financials and Corporate Update
08 May 2025 //
GLOBENEWSWIRE
Femasys Partners With CNY Fertility To Offer FemaSeed
19 Mar 2025 //
GLOBENEWSWIRE
Femasys Secures Distribution Partnerships for FemBloc® in Spain
18 Mar 2025 //
GLOBENEWSWIRE
Femasys Announces FemBloc Approval in Europe for Permanent Birth
13 Mar 2025 //
GLOBENEWSWIRE
Femasys Gets UK Nod For FemaSeed, Two Diagnostic Devices
11 Feb 2025 //
GLOBENEWSWIRE
Femasys Receives US Patent Allowance For FemaSeed® Infertility Use
16 Jan 2025 //
GLOBENEWSWIRE
Femasys Partners with HRC Fertility to Offer FemaSeed
03 Dec 2024 //
GLOBENEWSWIRE
Femasys Publishes Positive Data from FemaSeed® Infertility Trial
26 Nov 2024 //
GLOBENEWSWIRE
Femasys Announces Financial Results for Quarter Ended Sept 30
12 Nov 2024 //
GLOBENEWSWIRE
Femasys to Exhibit at Annual AAGL 2024 Global Conference
07 Nov 2024 //
GLOBENEWSWIRE
Femasys Announces U.S. Patent for FemBloc® Permanent Birth Control
01 Nov 2024 //
GLOBENEWSWIRE
Femasys Secures $1.3M Distribution Deal For FemaSeed In Spanish Market
11 Sep 2024 //
GLOBENEWSWIRE
Femasys Receives FDA Clearance For FemChec
09 Sep 2024 //
GLOBENEWSWIRE
Femasys to Join Fireside Chat at H.C. Wainwright Global Conference
03 Sep 2024 //
GLOBENEWSWIRE
Femasys Gets CE Mark and Canadian Approval for FemVue® MINI Assessment Solution
29 Aug 2024 //
GLOBENEWSWIRE
Femasys Hosts Congresswoman Lucy McBath at Georgia Headquarters
27 Aug 2024 //
GLOBENEWSWIRE
Femasys Announces Q2 2024 Results And Provides Corporate Update
08 Aug 2024 //
GLOBENEWSWIRE
Femasys to Participate in European Society of Human Reproduction and Embryology
27 Jun 2024 //
GLOBENEWSWIRE
Femasys Receives CE Mark For Four Women`s Health Products For EU
20 Jun 2024 //
GLOBENEWSWIRE
Femasys CEO Meets White House On Cancer Moonshot
17 May 2024 //
GLOBENEWSWIRE
Femasys CEO Meets With White House Gender Policy Council
16 May 2024 //
GLOBENEWSWIRE
Femasys Q1 2024 Financials And Corporate Update
09 May 2024 //
GLOBENEWSWIRE
Femasys Expands Commercial Management Team With New Hires
07 May 2024 //
GLOBENEWSWIRE
Femasys CEO Meets Congress On Women`s Health Initiatives
18 Apr 2024 //
GLOBENEWSWIRE
Femasys Announces Financial Results for Year Ended December 31, 2023
28 Mar 2024 //
GLOBENEWSWIRE
Femasys Invites to View Fireside Chat to Discuss the Infertility Treatment
21 Mar 2024 //
GLOBENEWSWIRE
Femasys Announces +ve Topline Data Pivotal Trial for its FDA-Cleared FemaSeed
20 Mar 2024 //
GLOBENEWSWIRE
Femasys to Participate in Chat to Discuss Infertility Treatment Landscape
13 Mar 2024 //
GLOBENEWSWIRE
Femasys Completes Commercial Procedure with FemaSeed Infertility Solution
06 Mar 2024 //
GLOBENEWSWIRE
Femasys™ FemaSeed Clearance Brings Timely Access to nfertility Treatment Option
28 Feb 2024 //
GLOBENEWSWIRE
Femasys Inc. Advances Commercial Readiness with Appointment of Richard Spector
06 Feb 2024 //
GLOBENEWSWIRE
Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at UC Davis Medical Center
26 Jan 2024 //
GLOBENEWSWIRE
Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at University of Utah
23 Jan 2024 //
GLOBENEWSWIRE
Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at Stanford Medicine
15 Dec 2023 //
GLOBENEWSWIRE
Femasys Announces the Appointment of James Liu, M.D., as Chief Medical Officer
30 Nov 2023 //
GLOBENEWSWIRE
Femasys Inc. Completes Enrollment of FemaSeed Pivotal Trial in Support of Launch
28 Nov 2023 //
GLOBENEWSWIRE
Femasys Secures Additional Financing with Strategic Investment from Investors
15 Nov 2023 //
GLOBENEWSWIRE
Femasys Inc. Announces Financial Results for the Third Quarter
14 Nov 2023 //
GLOBENEWSWIRE
Femasys Inc. EU MDR Final Audit Successfully Completed
26 Oct 2023 //
GLOBENEWSWIRE
